Survival with Polatuzumab, Bendamustine, and Rituximab in Non-GCB DLBCL
For patients with relapsed/refractory non-GCB DLBCL treated with polatuzumab vedotin, bendamustine, and rituximab (Pola-BR), median overall survival is approximately 12-13 months, with complete response rates of 32-40%.
Key Survival Data
The FDA-approved regimen of Pola-BR in relapsed/refractory DLBCL demonstrates the following outcomes 1:
- Median Overall Survival: 12.4 months (vs 4.7 months with BR alone)
- Complete Response Rate: 40% at end of treatment
- Hazard Ratio for Death: 0.42 (95% CI: 0.24-0.72) compared to BR alone
Updated long-term data with extended follow-up confirms these findings, showing median OS of 12.5 months in the extension cohort 2.
Non-GCB Specific Considerations
Importantly, the non-GCB subtype may actually derive particular benefit from polatuzumab-containing regimens. Recent 2025 NCCN guidelines highlight that in the mosunetuzumab + polatuzumab vedotin combination study, higher response rates were observed in non-GCB DLBCL (55%) compared with GCB DLBCL (36%) 3. This suggests that non-GCB biology may be more susceptible to anti-CD79b targeting with polatuzumab.
Similarly, in frontline therapy with PV-R-CHP, real-world data demonstrates improved progression-free survival specifically in patients with non-GCB DLBCL 4.
Real-World Performance
Real-world studies confirm the pivotal trial results 5, 6, 7:
- Overall Response Rate: 47-63%
- Complete Response Rate: 17-38%
- Median PFS: 10-11 months
- 1-year OS: 51-52%
- 2-year OS: 51-52%
Clinical Context and Alternatives
However, you should be aware that Pola-BR is no longer the optimal choice for transplant-ineligible relapsed/refractory DLBCL in 2025. The most recent NCCN guidelines (2025) now prioritize newer regimens with superior survival 3:
- Glofitamab + GemOx: Median OS 26 months
- Epcoritamab + GemOx: Median OS 22 months
- Mosunetuzumab + Polatuzumab: Median OS 23 months (particularly effective in non-GCB with 55% response rate)
These bispecific antibody-based combinations demonstrate nearly double the median OS compared to Pola-BR.
Safety Profile
The regimen carries manageable toxicity 1, 2:
- Grade 3-4 neutropenia and thrombocytopenia: Most common hematologic toxicities
- Peripheral neuropathy: Occurs in majority of patients but primarily grade 1-2
- Infections: Significant concern, with fatal adverse events in 4-12% of patients in various studies
Critical Pitfall
Do not use Pola-BR if the patient previously received polatuzumab vedotin in frontline therapy (Pola-R-CHP). The NCCN guidelines specifically note that efficacy data for re-exposure to polatuzumab is lacking, and this is increasingly relevant as Pola-R-CHP becomes standard frontline therapy 3.